Gastroretentive Drug Delivery Systems Outsourcing Market Report 2025

This Gastroretentive Drug Delivery Systems Outsourcing market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The gastroretentive drug delivery systems outsourcing market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.5 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to the rising incidence of stomach and small intestine disorders, rising drug delivery systems, rising prevalence of gastric cancer, rise in government initiatives, and increase in the number of hospitals.

The gastroretentive drug delivery systems outsourcing market size is expected to see strong growth in the next few years. It will grow to $2.03 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increase in the number of ambulatory centers, the focus on patient compliance and convenience, the rising incidence of chronic diseases, increasing personalized medicine, and the growing aging population. Major trends in the forecast period include advancements in polymer science, formulation technologies, bioadhesive systems, novel polymers, drug release modifiers, the development of gastroretentive dosage forms, the integration of digital health technologies, smart gastroretentive systems, and targeted drug delivery.

The growing prevalence of gastrointestinal disorders is expected to drive the expansion of the gastroretentive drug delivery systems outsourcing market. Gastrointestinal disorders encompass a wide range of diseases affecting the digestive system, including the stomach, liver, gallbladder, intestines, and pancreas. The rise in these disorders is attributed to factors such as aging populations, antibiotic use, infectious agents, dietary changes, stress, lifestyle factors, and obesity. Outsourcing gastroretentive drug delivery systems enables pharmaceutical companies to access the expertise and resources needed to address the increasing burden of gastrointestinal conditions, ultimately improving patient outcomes and quality of life. For instance, in January 2023, the American Cancer Society (ACS), a US-based health organization, reported a 3.18% increase in gastrointestinal cancers, rising to 348,840 cases from 338,090 in 2021 in the United States. Therefore, the rising prevalence of gastrointestinal disorders is driving the growth of the gastroretentive drug delivery systems outsourcing market.

Key players in the gastroretentive drug delivery systems outsourcing market are concentrating on developing innovative solutions, such as ready-to-fill (RTF) colon functional capsules, to improve drug delivery efficiency and enhance patient convenience. Ready-to-fill (RTF) colon functional capsules are pre-manufactured, empty capsules designed to be filled with specific formulations or active ingredients intended for targeted delivery to the colon. For example, in September 2024, Evonik, a Germany-based leader in advanced drug delivery, introduced its EUDRACAP colon functional capsules, designed to deliver oral medications directly to the ileo-colonic region. These capsules represent the first ready-to-fill option in the market, specifically intended to carry sensitive active ingredients like live biotherapeutic products (LBPs). Currently available in technical grade, a GMP-grade version is under development. EUDRACAP colon simplifies the oral drug development process by easing formulation and speeding up time to market, marking a significant step forward in gastroretentive drug delivery systems.

In August 2022, Catalent Inc., a pharmaceutical company headquartered in the United States, completed the acquisition of Metrics Contract Services (Metrics) for an estimated $475 million. Through this strategic move, Catalent intends to fortify its integrated capabilities in oral solid formulation development, manufacturing, and packaging, thereby augmenting its capacity to handle potent compounds and improving its capacity to satisfy customer demands and patient requirements. Metrics Contract Services, based in the United States, is a contract development and manufacturing organization (CDMO) that specializes in providing services for pharmaceutical product development, manufacturing, and analytical testing.

Major companies operating in the gastroretentive drug delivery systems outsourcing market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Evonik Industries AG, Alcon Inc., SGS SA, Lonza Group AG, FMC Corporation, Sun Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup Inc., Cadila Pharmaceuticals, Ashland Global Holdings Inc, Lupin Limited, Torrent Pharmaceuticals Ltd., Evotec SE, Colorcon Inc., Ranbaxy Laboratories Limited, Quotient Sciences Limited, Aenova Group, Vectura Group Ltd., Assertio Therapeutics Inc., Coating Place Inc., Xiromed LLC, SPI Pharma Inc.

North America was the largest region in the gastroretentive drug delivery systems outsourcing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroretentive drug delivery systems outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gastroretentive drug delivery systems outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Gastroretentive drug delivery systems outsourcing involves pharmaceutical firms engaging external service providers or contract research organizations (CROs) to create and produce drug delivery systems intended to extend the duration of medication within the gastrointestinal (GI) tract. These systems are crafted to boost drug absorption, enhance therapeutic effectiveness, and optimize patient results.

The primary categories of gastroretentive drug delivery systems outsourcing include floating systems, bioadhesive systems, and other variants. A floating drug delivery system (FDDS) is tailored to extend the retention period of medications in the stomach and upper gastrointestinal tract. These systems come in various dosage forms such as tablets, liquids, microspheres, capsules, and others, serving diverse applications such as gastroesophageal reflux disease (GERD), neurological disorders, and more. They are utilized by a range of end-users, including pharmaceutical companies, contract research organizations (CROs), and others.

The gastroretentive drug delivery systems outsourcing market research report is one of a series of new reports that provides gastroretentive drug delivery systems outsourcing market statistics, including gastroretentive drug delivery systems outsourcing industry global market size, regional shares, competitors with a gastroretentive drug delivery systems outsourcing market share, detailed gastroretentive drug delivery systems outsourcing market segments, market trends, and opportunities, and any further data you may need to thrive in the gastroretentive drug delivery systems outsourcing industry. This gastroretentive drug delivery systems outsourcing research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gastroretentive drug delivery systems outsourcing market consists of revenues earned by entities by providing services such as analytical and testing services, formulation development, quality assurance and control, and clinical trial services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastroretentive drug delivery systems outsourcing market also includes sales of bioadhesive systems, swelling systems, and high-density systems, and floating systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.